MicroRNA-375 and microRNA-221: Potential noncoding RNAs associated with antiproliferative activity of Benzyl isothiocyanate in pancreatic cancer

Genes and Cancer

Volumn 2, Issue 2, 2011, Pages 108-119

  Basu, Aruna ^a   Alder, Hansjuerg ^b   Khiyami, Amer ^c   Leahy, Patrick ^a   Croce, Carlo M ^b   Haldar, Subrata ^a,d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiproliferative effect; Benzyl isothiocyanate; IGFBP5; Micrornas; Pancreatic cancer; Pancreatic intraepithelial neoplasia

Indexed keywords

BENZYL ISOTHIOCYANATE; CAVEOLIN 1; MICRORNA; MICRORNA 221; MICRORNA 375; SOMATOMEDIN BINDING PROTEIN 5; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CAV 1 GENE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; GENE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IGFBP5 GENE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH; UPREGULATION;

CHICKEN ANEMIA VIRUS; MUS;

EID: 79960043599     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911409212     Document Type: Article

References (48)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-97.
2. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704-14.
3. Negrini M, Nicoloso MS, Calin GA. MicroRNAs and cancer: new paradigms in molecular oncology. Curr Opin Cell Biol. 2009;21:470-9.
4. Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene. 2006;25:6170-5.
5. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297:1901-8.
6. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26:4442-52.
7. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007;120:1046-54.
8. Basu A, Jiang X, Negrini M, Haldar S. MicroRNA-mediated regulation of pancreatic cancer cell proliferation. Oncol Lett. 2010;1: 565-8.
9. Kent OA, Mendell JT. A small piece in cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25:6188-96.
10. Cimmino A, Calin GA, Fabri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A.2005;102:13944-9.
11. Zhao JJ, Lin J, Yang H, et al. MicroRNA-221/222 negatively regulates estrogen receptor a and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008;283:31079-86.
12. Fornari F, Gramantieri L, Ferracin M, et al. miR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008;27:5651-61.
13. Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res. 2006;66:4309-18.
14. Qanungo S, Das M, Haldar S, Basu A. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis. 2005; 26:958-67.
15. Dhar A, Mehta S, Dhar G, et al. Crocetin inhibits pancreatic cancer cell proliferation and tumor progression in a xenograft mouse model. Mol Cancer Ther. 2009;8:315-23.
16. Basu A, Haldar S. 2-Methoxyestradiol mediated signaling network in pancreatic cancer. Front Biosci. 2009;14:2170-8.
17. Basu A, Haldar S. Dietary isothiocyanate mediated apoptosis of human cancer cells is associated with Bcl-xL phosphorylation. Int J Oncol. 2008;33:657-63.
18. Srivastava SK, Singh SV. Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cells. Carcinogenesis. 2004;25:1701-9.
19. Blower PE, Chung J-H, Verducci JS, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008;7:1-9.
20. Dai Z, Barbacioru C, Huang Y, Sadee W. Prediction of anticancer drug potency from expression of genes involved in growth factor signaling. Pharm Res. 2006;23:336-49.
21. Dai Z, Huang Y, Sadee W. Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem. 2004;4:1347-56.
22. Sun M, Estrov Z, Ji Y, et al. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008;7:464-73.
23. Scott GK, Mattie MD, Berger CE, et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res.2006;66:1277-81.
24. Garzon R, Pichiorri F, Palumbo T, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene. 2007;26:4148-57.
25. Weidhaas JB, Babar I, Nallur P, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res.2007;67:11111-6.
26. Tsang WP, Kwok TT. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem.2010;21:140-6.
27. Basu A, Haldar S. Antiproliferative and proapoptotic effects of benzyl isothiocyanate on human pancreatic cancer cells is linked to death receptor activation and RasGAP/Rac1 down modulation. Int J Oncol.2009;35:593-9.
28. Avissar M, Christensen BC, Kelsey KT, et al. MicroRNA expression is predictive of head and neck squamous cell carcinoma. Clin Cancer Res. 2009;15:2850-5.
29. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437-50.
30. Gidekel Friedlander SY, Chu GC, Snyder EL, et al. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell. 2009;16:379-89.
31. Mercatelli N, Coppola M, Bonci D, et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One. 2008;3:1-10.
32. Munshi A, Hobbs M, Meyn RE. Clonogenic cell survival assay. Methods Mol Med. 2005;110:21-8.
33. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol. 2005;288:C494-506.
34. Beattie J, Allan GJ, Lochrie JD, Flint DJ. Insulin-like growth factorbinding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J. 2006;395:1-19.
35. Tanase CP. Caveolin-1: a marker for pancreatic cancer diagnosis. Expert Rev Mol Diagn. 2008;8:395-404.
36. Johnson SK, Haun RS. Insulin-like growth factor binding protein-5 influences pancreatic cancer cell growth. World J Gastroenterol.2009;15:3355-66.
37. Steele R, Mott JL, Ray RB. MBP-1 upregulates miR-29b, which represses Mcl-1, collagens, and matrix metalloproteinase-2 in prostate cancer cells. Genes Cancer. 2010;1:381-7.
38. Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432;226-30.
39. Lynn FC, Skewes-Cox P, Kosaka Y, et al. MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes.2007;56:2938-45.
40. Tsukamoto Y, Nakada C, Noguchi T, et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3?. Cancer Res. 2010;70:2339-49.
41. Jones S, Zhang X, Parsons DW, et al. Core signaling pathway in human pancreatic cancers revealed by global genomic analyses. Science.2008;321:1801-6.
42. Shields JM, Pruitt K, McFall A, et al. Understanding Ras: 'it ain't over till it's over'. Trends Cell Biol. 2000;10:147-54.
43. Hruban RH, Adsay NV, bores-Saavedra J, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res. 2006;66: 95-106.
44. Park JK, Lee EJ, Esau C, et al. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinomas. Pancreas.2009;38:190-9.
45. Hsu JD, Kao SH, Ou TT, et al. Gallic acid induces G2/M phase arrest of breast cancer cell MCF-7 through stabilization of p27 (kip1) attributed to disruption of p27(Kip1)/Skp2 complex. J Agric Food Chem. Epub 2011 Feb 7.
46. Karamitopolou E, Zlobec I, Tomillo L, et al. Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). Pathology.2010;42:229-34.
47. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov.2010;9:775-89.
48. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C[T]] method. Methods. 2001;25:402-8.